Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이현 | - |
dc.date.accessioned | 2019-12-10T20:47:22Z | - |
dc.date.available | 2019-12-10T20:47:22Z | - |
dc.date.issued | 2018-12 | - |
dc.identifier.citation | JOURNAL OF THORACIC DISEASE, v. 10, no. 12, page. 6522-+ | en_US |
dc.identifier.issn | 2072-1439 | - |
dc.identifier.issn | 2077-6624 | - |
dc.identifier.uri | http://jtd.amegroups.com/article/view/25541/19432 | - |
dc.identifier.uri | https://repository.hanyang.ac.kr/handle/20.500.11754/121200 | - |
dc.description.abstract | Background: A single long-acting bronchodilator, ultra-long acting muscarinic antagonist (ultra-LAMA) or ultra-long acting beta(2)-agonist (ultra-LABA) is preferred for the initial treatment of patients with chronic obstructive pulmonary disease (COPD); however, there are few head-to-head comparative studies between the two. Here, a meta-analysis of randomized controlled trials was performed to compare the clinical efficacy between ultra-LABA and ultra-LAMA in patients with moderate-to-severe COPD.Methods: MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials were searched (to March 1, 2017) to identify all published randomized controlled trials.Results: Of the 12,906 articles found by searching the databases, we obtained data from 10,591 patients with COPD (LABA, n= 5,058; LAMA, n= 5,533) in seven published studies. Our results showed that COPD exacerbation were significantly lower in patients taking ultra-LAMA than those taking ultra-LABA (odds ratio = 0.857, P=0.0008). However, no significant differences were observed between ultra-LAMA and ultra-LABA patients regarding improvement in trough forced expiratory volume in 1 s, the transitional dyspnea index, or St. George's Respiratory Questionnaire score.Conclusions: This study suggests that COPD exacerbation occurred less often in patients taking an ultra-LAMA than in those taking an ultra-LABA with similar efficacy of lung function and quality of life. | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | AME PUBL CO | en_US |
dc.subject | Chronic obstructive pulmonary disease (COPD) | en_US |
dc.subject | ultra-long acting beta(2)-agonist (LABA) | en_US |
dc.subject | ultra-long-acting muscarinic antagonist (LAMA) | en_US |
dc.subject | meta-analysis | en_US |
dc.title | Comparison of clinical efficacy between ultra-LABAs and ultra-LAMAs in COPD: a systemic review with meta-analysis of randomized controlled trials | en_US |
dc.type | Article | en_US |
dc.relation.no | 12 | - |
dc.relation.volume | 10 | - |
dc.identifier.doi | 10.21037/jtd.2018.11.50 | - |
dc.relation.page | 6522-6522 | - |
dc.relation.journal | JOURNAL OF THORACIC DISEASE | - |
dc.contributor.googleauthor | Cho, Eun Yeong | - |
dc.contributor.googleauthor | Kim, Se Yong | - |
dc.contributor.googleauthor | Kim, Min-Ji | - |
dc.contributor.googleauthor | Kim, Seonwoo | - |
dc.contributor.googleauthor | Park, Dong Ah | - |
dc.contributor.googleauthor | Yoo, Kwang Ha | - |
dc.contributor.googleauthor | Park, Yong Bum | - |
dc.contributor.googleauthor | Hwang, Yong Il | - |
dc.contributor.googleauthor | Rhee, Chin Kook | - |
dc.contributor.googleauthor | Lee, Hyun | - |
dc.relation.code | 2018010356 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF MEDICINE[S] | - |
dc.sector.department | DEPARTMENT OF MEDICINE | - |
dc.identifier.pid | namuhanayeyo | - |
dc.identifier.researcherID | G-1336-2018 | - |
dc.identifier.orcid | http://orcid.org/0000-0002-1269-0913 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.